

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
31 August 2023 (31.08.2023)



(10) International Publication Number
WO 2023/161649 A1

(51) International Patent Classification:

A61K 39/125 (2006.01) A61P 31/16 (2006.01)
C07K 14/095 (2006.01)

(21) International Application Number:

PCT/GB2023/050427

(22) International Filing Date:

27 February 2023 (27.02.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2202738.7 28 February 2022 (28.02.2022) GB

(71) Applicant: **IP2IPO INNOVATIONS LIMITED**

[GB/GB]; 2nd Floor, 3 Pancras Square, King's Cross, London
NIC 4AG (GB).

(72) Inventors: **JOHNSTON, Sebastian**; Imperial College

London, Norfolk Place, London W2 1PG (GB). **SHAW,
Stephen**; Apollo Therapeutics, 22 Station Road, Cambridge
Cambridgeshire CB1 2JD (GB). **HAMBLIN, Paul**; GSK,
Gunnels Wood Road, Stevenage SG1 2NY (GB). **BOR-**

NOT, Aurelie; GSK, Gunnels Wood Road, Stevenage SG1
2NY (GB). **RICCHIUTO, Piero**; Alexion Pharmaceuti-
cals, 121 Seaport Blvd, Boston, Massachusetts 02210 (US).
BENDTSEN, Claus; AstraZeneca, Pepparedsleden 1, 431
50 Mölndal (SE).


(74) Agent: **HUTTER, Anton**; Venner Shipley LLP, The Sur-
rey Research Park, 5 Stirling House, Stirling Road, Guild-
ford Surrey GU2 7RF (GB).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(54) Title: RHINOVIRUS VACCINE

Figure 1



(57) Abstract: The invention relates to immunogenic compositions, and in particular, to immunogenic compositions for preventing, treating or ameliorating human rhinovirus (RV) infections. The invention is especially concerned with RV VPo peptides (or proteins) and polynucleotides encoding such peptides, and their use in immunogenic compositions for eliciting an immune response and preventing rhinovirus infections.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*